Skip to content
Screener

Recursion Pharmaceuticals, Inc. RXRX Q1 2025 earnings

Reported May 5, 2025 · Before market open

Revenue$14.7MBeat by $785.0K
EPS-$0.50Miss by $0.06
Revenue estimate$14.0M
EPS estimate-$0.44

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$14.2M
EPS estimate-$0.24

Financials

Q1 2025

Income statement

See full
Revenue$14.7M+6.9%
Gross profit-$7.1M-370%
Operating income-$191.4M-98.6%
Net income-$202.5M-122%
EPS (diluted)-$0.50-28.2%

Balance sheet

See full
Cash & equivalents$509.2M+66.3%
Total debt$117.5M+131%
Total equity$933.9M+133%
Total assets$1.3B+134%

Cash flow

See full
Operating cash flow-$132.0M-29.0%
CapEx$1.8M-72.5%
Free cash flow-$133.8M-22.8%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$2.13B-9.6%
Enterprise value$1.73B-17.3%
P/S35.6×-15.3×

Profitability

See full
Operating margin-960.1%+209pp
Net margin-961.3%+329pp
FCF margin-665.2%-42.7pp

Returns & leverage

See full
Return on equity-86.1%+0.9pp
Debt / equity0.1×0.0×
Current ratio4.1×-0.5×

Segments

By product

See full
Operating revenue$14.8M+9.8%
Grant revenue-$73.0K-124%

By segment

See full
Reportable Segment$14.7M+6.9%

By geography

See full
Other--100%

FAQ

When did Recursion Pharmaceuticals, Inc. report Q1 2025 earnings?
Recursion Pharmaceuticals, Inc. (RXRX) reported Q1 2025 earnings on May 5, 2025 before market open.
What were Recursion Pharmaceuticals, Inc.'s Q1 2025 revenue and EPS?
Recursion Pharmaceuticals, Inc. reported revenue of $14.7M and eps of $-0.50 for Q1 2025.
Did Recursion Pharmaceuticals, Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $14.0M by $785.0K. EPS missed the consensus estimate of $-0.44 by $0.06.
How did Recursion Pharmaceuticals, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 6.9% from $13.8M a year earlier and eps declined 28.2% from $-0.39.
Where can I find Recursion Pharmaceuticals, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001601830-25-000074) and the 10-Q periodic report (0001601830-25-000075) directly on SEC EDGAR. The filing index links above go to sec.gov.